Communications Medicine (Jul 2023)

Genomic epidemiology of SARS-CoV-2 variants during the first two years of the pandemic in Colombia

  • Cinthy Jimenez-Silva,
  • Ricardo Rivero,
  • Jordan Douglas,
  • Remco Bouckaert,
  • Ch. Julian Villabona-Arenas,
  • Katherine E. Atkins,
  • Bertha Gastelbondo,
  • Alfonso Calderon,
  • Camilo Guzman,
  • Daniel Echeverri-De la Hoz,
  • Marina Muñoz,
  • Nathalia Ballesteros,
  • Sergio Castañeda,
  • Luz H. Patiño,
  • Angie Ramirez,
  • Nicolas Luna,
  • Alberto Paniz-Mondolfi,
  • Hector Serrano-Coll,
  • Juan David Ramirez,
  • Salim Mattar,
  • Alexei J. Drummond

DOI
https://doi.org/10.1038/s43856-023-00328-3
Journal volume & issue
Vol. 3, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background The emergence of highly transmissible SARS-CoV-2 variants has led to surges in cases and the need for global genomic surveillance. While some variants rapidly spread worldwide, other variants only persist nationally. There is a need for more fine-scale analysis to understand transmission dynamics at a country scale. For instance, the Mu variant of interest, also known as lineage B.1.621, was first detected in Colombia and was responsible for a large local wave but only a few sporadic cases elsewhere. Methods To better understand the epidemiology of SARS-Cov-2 variants in Colombia, we used 14,049 complete SARS-CoV-2 genomes from the 32 states of Colombia. We performed Bayesian phylodynamic analyses to estimate the time of variants’ introduction, their respective effective reproductive number, and effective population size, and the impact of disease control measures. Results Here, we detect a total of 188 SARS-CoV-2 Pango lineages circulating in Colombia since the pandemic’s start. We show that the effective reproduction number oscillated drastically throughout the first two years of the pandemic, with Mu showing the highest transmissibility (Re and growth rate estimation). Conclusions Our results reinforce that genomic surveillance programs are essential for countries to make evidence-driven interventions toward the emergence and circulation of novel SARS-CoV-2 variants.